Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Where’s The Suffix? Valeant’s Siliq Approved Without Four-Letter Identifier

Executive Summary

Psoriasis treatment brodalumab is first novel biologic approved since US FDA released its final guidance on nonproprietary naming for new biologics and biosimilars; agency says it didn't want to delay the approval by taking more time to develop a suffix.


Related Content

Keeping Track: A Second Straight Burst Of FDA Approvals
Novel Biologics Will Get Suffixes (Or At Least One Did)
Novel Biologics In US Might Not Start Getting Suffixes Until August
Ocrevus Launching Quickly Even After Manufacturing Worries Delayed US Approval
US FDA Approval Of Valeant’s Siliq Comes With REMS, Boxed Warning
FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
Valeant’s Brodalumab Delayed By FDA As REMS Is Negotiated
Valeant's Siliq Clears FDA Panel But Faces Prospect Of Post-Marketing Registry


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts